22nd Century (XXII) falls 1.59% in Light Trading on January 14

Equities Staff  |

Today, 22nd Century Group Inc Inc’s (NYSE: XXII) stock fell $0.04, accounting for a 1.59% decrease. 22nd Century opened at $2.51 before trading between $2.52 and $2.39 throughout Friday’s session. The activity saw 22nd Century’s market cap fall to $401,956,643 on 1,654,047 shares -below their 30-day average of 7,832,180.

About 22nd Century Group Inc

22nd Century is a plant biotechnology company focused on technology which allows it to decrease the level of nicotine in tobacco plants and modify the levels of cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. The Company's primary mission in tobacco is to reduce the harm caused by smoking. The Company's primary mission in hemp/cannabis is to develop proprietary hemp strains for important new medicines and agricultural crops.

Visit 22nd Century Group Inc's profile for more information.

About The New York Stock Exchange

The New York Stock Exchange is the world’s largest stock exchange by market value at over $26 trillion. It is also the leader for initial public offerings, with $82 billion raised in 2020, including six of the seven largest technology deals. 63% of SPAC proceeds in 2020 were raised on the NYSE, including the six largest transactions.

To get more information on 22nd Century Group Inc and to follow the company's latest updates, you can visit the company's profile page here: 22nd Century Group Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Algoma Steel Upgrades Power Plant in Transition to Green Steelmaking
Insulet Gets FDA Clearance for Omnipod 5 Automated Insulin Delivery System
Russell 2000 Enters Bear Market Territory for First Time in Nearly Two Years
TG Therapeutics Tumbles 40% on Partial Clinical Trial Hold
Huawei Says Carrier Business Stable as Revenues Decline: Jeff Kagan
Time To Reconsider Galapagos as New CEO Paul Stoffels Named
Global Politics Could Drive Extreme Market Volatility in 2022
Stock Stage Sharp Monday Afternoon Rally To Erase Morning Losses



Market Movers

Sponsored Financial Content